Semaglutide Use in Elderly Obese Patients

NCT05302596 · Completed

Last updated 2026-05-28

This clinical trial tests whether semaglutide, a medication, affects body fat and muscle composition in older adults who are obese.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 16 people

Who can join Ages 65+ · all sexes Healthy volunteers accepted.

Timeline Started 2022-09 · est. completion 2024-10

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05302596 ↗

Description as written by the study sponsor.

This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly obese subjects on body weight and body composition as assessed by DEXA.

Treatments tested

Semaglutide Pen Injector also known as Ozempic Drug

semaglutide (up to 1mg) once weekly injection added to the standard of care weight loss program. Semaglutide dose will be started at 0.25 mg dose during the baseline visit and doubled every 2 weeks up to 1mg dose or up to maximum tolerable dose for total of 16 weeks of intervention

Main thing measured	Body Composition as Total Fat Mass/ Total Fat-free Mass Ratio
Sponsor	State University of New York at Buffalo
Conditions studied	Obesity, Aging
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05302596 ↗